Literature DB >> 8285139

Effects of a highly selective plasma kallikrein inhibitor on collagen-induced arthritis in mice.

Y Fujimori1, T Nakamura, K Shimizu, T Yamamuro, K Wanaka, S Okamoto, Y Katsuura.   

Abstract

A study was conducted to evaluate the effects of a new, highly selective plasma kallikrein inhibitor, PKSI-527, on collagen-induced arthritis (CIA) in mice. PKSI-527 or indomethacin was administered daily intraperitoneally from day 20 postimmunization. Clinical evaluation was performed, and two of the components of the kallikrein-kinin system, high-molecular-weight (HMW) kininogen and plasma prekallikrein, were assayed. PKSI-527, as well as indomethacin, reduced the severity of arthritis significantly. PKSI-527, but not indomethacin, restored consumed components of the kallikrein-kinin system. These results suggest that PKSI-527 suppresses CIA by modifying the kallikrein-kinin system and PKSI-527 as a synthetic plasma kallikrein inhibitor would be a valuable tool to study the mechanism of inflammation of arthritic diseases.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8285139     DOI： 10.1007/BF01975713

Source DB:  PubMed          Journal:  Agents Actions        ISSN： 0065-4299


  28 in total

1.  Effects of FK-506 on collagen arthritis in mice.

Authors:  K Takagishi; M Yamamoto; A Nishimura; G Yamasaki; N Kanazawa; T Hotokebuchi; N Kaibara
Journal:  Transplant Proc       Date:  1989-02       Impact factor: 1.066

2.  The effect of treatment with interferon-gamma on type II collagen-induced arthritis.

Authors:  H Nakajima; H Takamori; Y Hiyama; W Tsukada
Journal:  Clin Exp Immunol       Date:  1990-09       Impact factor: 4.330

3.  Bradykinin is increased during acute and chronic inflammation: therapeutic implications.

Authors:  K M Hargreaves; E S Troullos; R A Dionne; E A Schmidt; S C Schafer; J L Joris
Journal:  Clin Pharmacol Ther       Date:  1988-12       Impact factor: 6.875

4.  The effect of etodolac on type II collagen-induced arthritis in mice.

Authors:  P H Wooley; J D Whalen; J L Zimmerman; T M Champion
Journal:  Agents Actions       Date:  1987-08

Review 5.  Biochemistry and applications of aprotinin, the kallikrein inhibitor from bovine organs.

Authors:  H Fritz; G Wunderer
Journal:  Arzneimittelforschung       Date:  1983

6.  Enzyme immunoassay of bradykinin using beta-D-galactosidase as a labeling enzyme.

Authors:  A Ueno; S Oh-ishi; T Kitagawa; M Katori
Journal:  Biochem Pharmacol       Date:  1981-06-15       Impact factor: 5.858

7.  Evaluation of the effects of various anti-arthritic drugs on type II collagen-induced mouse arthritis model.

Authors:  K Phadke; R L Fouts; J E Parrish; L D Butler
Journal:  Immunopharmacology       Date:  1985-08

8.  Arthritis in MRL/LPR mice and in collagen II sensitized DBA-1 mice and their use in pharmacology.

Authors:  C Rordorf; A Pataki; V Nogues; F Schlager; U Feige; M Glatt
Journal:  Int J Tissue React       Date:  1987

9.  Methylacetylenic putrescine (MAP), an inhibitor of polyamine biosynthesis, prevents the development of collagen-induced arthritis.

Authors:  J A Wolos; D E Logan; T L Bowlin
Journal:  Cell Immunol       Date:  1990-02       Impact factor: 4.868

10.  Effects of cyclosporin on collagen induced arthritis in mice.

Authors:  K Takagishi; N Kaibara; T Hotokebuchi; C Arita; M Morinaga; K Arai
Journal:  Ann Rheum Dis       Date:  1986-04       Impact factor: 19.103
View more
  2 in total

1.  The Coagulation Factors Fibrinogen, Thrombin, and Factor XII in Inflammatory Disorders-A Systematic Review.

Authors:  Kerstin Göbel; Susann Eichler; Heinz Wiendl; Triantafyllos Chavakis; Christoph Kleinschnitz; Sven G Meuth
Journal:  Front Immunol       Date:  2018-07-26       Impact factor: 7.561

2.  Ecotin, a microbial inhibitor of serine proteases, blocks multiple complement dependent and independent microbicidal activities of human serum.

Authors:  Zoltán Attila Nagy; Dávid Szakács; Eszter Boros; Dávid Héja; Eszter Vígh; Noémi Sándor; Mihály Józsi; Gábor Oroszlán; József Dobó; Péter Gál; Gábor Pál
Journal:  PLoS Pathog       Date:  2019-12-20       Impact factor: 6.823
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.